Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation

doi:10.1016/0092-8674(89)90867-2

Cell

Volume 59, Issue 1, 6 October 1989, Pages 33-43

https://doi.org/10.1016/0092-8674(89)90867-2 Get rights and content

Abstract

We have located the distal boundary of the tyrosine kinase domain of the EGF receptor and have identified a distinct sequence in the C′ terminus required for EGF-dependent receptor internalization, leading to receptor down-regulation and degradation. Within this receptor domain, an 18 amino acid highly negatively charged region of predicted helical structure is required both for endocytosis via a high-affinity, saturable pathway and for ligand-stimulated increases in cytosolic calcium. In contrast to kinase-inactive, internalization-competent receptors, kinase-active, internalization-defective receptors effectively signaled gene transcription, morphological transformation, and growth. These observations support the hypothesis that mitogenic responses to EGF are mediated by activation of the intrinsic protein tyrosine kinase activity of the membrane-bound receptor, with ligand-induced internalization serving to terminate the signal.

References (47)

P.J. Bertics et al.
Self-phosphorylation enhances the protein-tyrosine kinase activity of the epidermal growth factor receptor
J. Biol. Chem.
(1985)
R. Brachmann et al.
Transmembrane TGF-α precursors activate $EGF TGF -α$ receptors
Cell
(1989)
Y. Chapron et al.
Tyrosine protein kinase activity of the EGF receptor is required to induce activation of receptor-operated calcium channels
Biochem. Biophys. Res. Commun.
(1989)
P.P. Di Fiore et al.
Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells
Cell
(1987)
J. Garnier et al.
Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins
J. Mol. Biol.
(1978)
G. Gill et al.
Mutants of GAL4 protein altered in an activation function
Cell
(1987)
J.R. Glenney et al.
Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies
Cell
(1988)
G. Grynkiewicz et al.
A new generation of Ca²⁺ indicators with greatly improved fluorescence properties
J. Biol. Chem.
(1985)
H.T. Haigler et al.
Dansylcadaverine inhibits internalization of ¹²⁵I-epidermal growth factor in BALB 3T3 cells
J. Biol. Chem.
(1980)
A.M. Honegger et al.
Point mutation at the ATP binding site of EGF receptor abolishes proteintyrosine kinase activity and alters cellular routing
Cell
(1987)

T. Hunter et al.

Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells

Cell

(1981)

C.R. Lin et al.

Protein kinase C phosphorylation at Thr 654 of the unoccupied EGF receptor and EGF binding regulate functional receptor loss by independent mechanisms

Cell

(1986)

E. Livneh et al.

Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells

J. Biol. Chem.

(1986)

S.A. Mendoza et al.

Measurement of ion flux and concentration in fibroblastic cells

Meth. Enzymol.

(1987)

W.H. Moolenaar et al.

Growth factors immediately raise cytoplasmic free Ca²⁺ in human fibroblasts

J. Biol. Chem.

(1984)

L.K. Opresko et al.

Receptor-mediated endocytosis in Xenopus oocytes. II. Evidence for two novel mechanisms of hormonal regulation

J. Biol. Chem.

(1987)

D.S. Russell et al.

The protein-tyrosine kinase activity of the insulin receptor is necessary for insulin-mediated receptor down-regulation

J. Biol. Chem.

(1987)

N. Savion et al.

Nuclear accumulation of epidermal growth factor in cultured bovine corneal endothelial and granulosa cells

J. Biol. Chem.

(1981)

H.S. Wiley et al.

The endocytotic rate constant: a cellular parameter for quantitating receptor-mediated endocytosis

J. Biol. Chem.

(1982)

S.T. Wong et al.

The TGF-α precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction

Cell

(1989)

G. Carpenter et al.

Epidermal growth factor

Annu. Rev. Biochem.

(1979)

W.S. Chen et al.

Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor

Nature

(1987)

P.Y. Chou et al.

Prediction of protein conformation

Biochemistry

(1974)

Cited by (344)

Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations
2023, Cytokine and Growth Factor Reviews
Epidermal growth factor receptor (EGFR) mutation is the most common driver mutation in non-small cell lung cancer (NSCLC). The first-line therapy for advanced NSCLC patients with EGFR-sensitive mutation is the EGFR tyrosine kinase inhibitor (EGFR-TKI). However, most NSCLC patients with EGFR mutation will develop resistant mutations in EGFR-TKI therapy. With further studies, resistance mechanisms represented by EGFR-T790M mutations have revealed the impact of EGFR mutations in situ on EGFR-TKIs sensitivity. The third-generation EGFR-TKIs inhibit both EGFR-sensitive mutations and T790M mutations. The emergence of novel mutations such as EGFR-C797S and EGFR-L718Q may decrease efficacy. Searching for new targets to overcome EGFR-TKI resistance becomes a key challenge. Therefore, an in-depth understanding of the regulatory mechanisms of EGFR is essential to find novel targets to overcome drug-resistant mutations in EGFR-TKIs. EGFR, as a receptor-type tyrosine kinase, undergoes homo/heterodimerization and autophosphorylation upon binding to ligands, which activates multiple downstream signaling pathways. Interestingly, there is growing evidence that the kinase activity of EGFR is affected not only by phosphorylation but also by various post-translational modifications (PTMs, such as S-palmitoylation, S-nitrosylation, Methylation, etc.). In this review, we systematically review the effects of different protein PTMs on EGFR kinase activity and its functionality and suggest that influencing EGFR kinase activity by modulating multiple EGFR sites are potential targets to overcome EGFR-TKIs resistance mutations.
Exploration and validation of Taraxacum mongolicum anti-cancer effect
2022, Computers in Biology and Medicine
Taraxacum mongolicum gained a lot of concern and was applied in 93 formulas in China due to its fame as a traditional Chinese medicine. The earliest recorded application of Taraxacum mongolicum was traced back to the Han dynasty. Generations of doctors boosted the usage and enriched the pharmacological mechanism. Clinical application of the Taraxacum mongolicum is flourishing as it treats multiple diseases. This study aims to explore the anti-cancer effect, retrieve the active ingredients and screen the key targets of Taraxacum mongolicum in cancer therapy. We collected and evaluated 10 key active compounds to investigate the anti-cancer effect via 69 significant targets and a variety of biological processes and pathways. Gene Ontology (GO) enrichment analysis uncovered targets associated with protein phosphorylation, cell proliferation and apoptotic processes via regulation of kinases, ATP and enzyme binding activities. Half of the top 20 enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were directly involved in cancer. Based on standard selection criteria, seven hub targets were obtained. These targets functioned through distinct patterns and pathways in realizing the anti-cancer effect. Molecular docking was conducted to validate the potential combination between compounds and hub targets to explore the pharmacological mechanism of key compounds in Taraxacum mongolicum against cancer. In summary, our findings indicate that the famous and widely used Chinese herb, Taraxacum mongolicum, shows good anti-cancer effect through its active compounds, targeted genes, and multiple involved biological processes. The results may provide a theoretical basis for subsequent experimental validation and drug development of Taraxacum mongolicum extract against cancer.
Molecular mechanism of Huaihuasan in treatment of ulcerative colitis based on network pharmacology and molecular docking
2021, Phytomedicine Plus
Citation Excerpt :
Another core EGFR is one of four members of the ErbB family and is well known to facilitate tumorigenesis and cancer progression. As the signal downstream of PI3K, EGFR binding receptor tyrosine kinase and activating several signaling cascades (Chen et al., 1989), including PI3K-Akt signaling pathway and NF-κB signaling pathway (Runkle et al., 2016; Habib et al., 2001). In addition, 3 core components can stably dock with AKT1 and EGFR, respectively.
Huaihuasan (HHS) is a Traditional Chinese Medicine formula for ulcerative colitis (UC). However, the pharmacology and molecular mechanism of HHS on ulcerative colitis still unclear.
Implement network pharmacology and molecular docking for revealing main active components of Huaihuasan against ulcerative colitis and to explore therapeutic mechanism.
TCMSP, PubChem, Swiss Target Prediction and GeneCards are utilized to search the active components and effective targets of HHS and ulcerative colitis. The co-targets between HHS and ulcerative colitis are obtained by Draw Venn Diagram. STRING database is intended to draw the PPI network. To obtain the core targets, topological analysis is used by Cytoscape 3.7.2. GO and KEGG enrichment pathway analysis was performed to Metascape platform, and molecular docking through Autodock Vina 1.1.2 finished.
21 active components with 211 effective targets of HHS, and 2325 effective targets of ulcerative colitis were screened. The Venn analysis was contained 89 co-targets. Enrichment analysis showed that HHS played a role in pathways in cancer, proteoglycans in cancer, PI3K-Akt signaling pathway, etc. Finally, two targets (AKT1 and EGFR) were successfully docked with 3 core components (isorhamnetin, kaempferol, quercetin), respectively.
HHS can act on multiple targets through multi-pathway, so as to perform its therapeutic role in ulcerative colitis.
Ziyuglycoside II inhibits the growth of digestive system cancer cells through multiple mechanisms
2021, Chinese Journal of Natural Medicines
Digestive system cancers, including liver, gastric, colon, esophageal and pancreatic cancers, are the leading cause of cancers with high morbidity and mortality, and the question of their clinical treatment is still open. Previous studies have indicated that Ziyuglycoside II (ZYG II), the major bioactive ingredient extract from Sanguisorba officinalis L., significantly inhibits the growth of various cancer cells. However, the selective anti-tumor effects of ZYG II against digestive system cancers are not systemically investigated. In this study, we reported the anti-cancer effect of ZYG II on esophageal cancer cells (OE21), cholangiocarcinoma cells (HuCCT1), gastric cancer cells (BGC-823), liver cancer cells (HepG2), human colonic cancer cells (HCT116), and pancreatic cancer cells (PANC-1). We also found that ZYG II induced cell cycle arrest, oxidative stress and mitochondrial apoptosis. Network pharmacology analysis suggested that UBC, EGFR and IKBKG are predicted targets of ZYG II. EGFR signaling was suggested as the critical pathway underlying the anti-cancer effects of ZYG II and both docking simulation and western blot analysis demonstrated that ZYG II was a potential EGFR inhibitor. Furthermore, our results showed synergistic inhibitory effects of ZYG II and chemotherapy 5-FU on the growth of cancer cells. In summary, ZYG II are effective anti-tumor agents against digestive cancers. Further systemic evaluation of the anti-cancer activities in vitro and in vivo and characterization of underlying mechanism will promote the development of novel supplementary therapeutic strategies based on ZYG II for the treatment of digestive system cancers.
Insight into the potential antineoplastic mechanism of phycocyanin in non-small cell lung carcinoma A549 cells based on micro-RNA sequencing
2020, Journal of Functional Foods
Citation Excerpt :
As tumor suppressor miRNA, miR-1231 down-regulated in glioma, prostate cancer, and pancreatic cancer (Wang, Zhang, Guo, Feng, & Zhao, 2020; Wang, Wu, Luo, & Hu, 2018; Zheng et al., 2016) was the second most overexpressed miRNA in phycocyanin-treated A549 cells (Table S2). It has been reported that the expression of miR-1231 is negatively correlated with EGFR levels, and overexpression of miR-1231 dramatically down-regulated glioma proliferation by targeting EGFR, an important receptor protein which activates several signaling cascades to convert extracellular cues into appropriate cellular responses (Chen et al., 1989). Interestingly, Wang et al. found out that miR-1231 also directly targeted EGFR in prostate cancer cells (Wang et al., 2020).
Phycocyanin is a type of marine functional food additive, exerting good antitumor property. However, its antineoplastic mechanism in non-small cell lung cancer (NSCLC) remains unclear. In this work, a high-throughput micro-RNA sequencing was employed to analyze key miRNAs regulated by phycocyanin in A549 cells for the first time. Results showed that a total of 61 miRNAs were differentially expressed between control and phycocyanin-treated cells, including 18 up-regulated and 43 down-regulated miRNAs. Subsequently, 483 validated target genes were predicted. Strikingly, protein–protein interaction analysis showed that target genes like EGFR, CDK2, POLR2E, TP53, and MED28 occupied high degrees in networks, which were predicted regulated by miR-1249-5p, miR-1231, miR-547-5p, and miR-93-5p. Furthermore, qRT-PCR showed strong consistent expression trends of differential miRNAs with miRNA-seq results. Consequently, this study significantly advances our understanding of the regulatory mechanisms of phycocyanin, especially with regard to miRNAs, and also lays a theoretical foundation for the treatment of NSCLC.
Characterization of two splice variants of EGFR and their effects on the growth of the razor clam
2018, Aquaculture and Fisheries
Citation Excerpt :
PCNA has been proposed to be a reliable indicator for cell proliferation as it is associated with proteins that control the G1 phase of the cell cycle, confirming DNA replication and cell division (Celis, Madsen, Celis, Nielsen & Gesser, 1987). A kinase such as p38MAPK is activated after changes to the serine phosphorylation sites in EGFR (Winogradkatz & Levitzki, 2006), which induces EGFR internalization and activates different pathways (Chen et al., 1989). Cancer cells with a mutation in EGFR survive through the activation of the AKT or STAT3 pathway (Akca, Tani, Hishida, Matsumoto & Yokota, 2006).
The epidermal growth factor receptor (EGFR) plays a vital role in cell growth, proliferation, and body growth. In this study, two EGFR isoforms (Sc-EGFR-1a and Sc-EGFR-1b) were obtained from Sinonovacula constricta. Sequence analysis of the coding region of Sc-EGFRs, revealed the 2 isoforms were generated from a common gene by alternative splicing and that one form possessed an extra 81 bp that corresponded to an insertion of 27 amino acids in the C-terminus. Expression of the Sc-EGFR isoforms were detectable in the early embryo stages and increased in the middle-late stages. Both isoforms were widely expressed in tissues, but the highest levels were detected in the siphon. Although both isoforms had a typical extracellular region, transmembrane region, and intracellular region, the insertion/deletion of 27 aa in the C-terminus changed the phosphorylation sites and may have influenced downstream kinase activities. In vitro, the proliferating cell nuclear antigen indicator and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that HEK293T cells transfected with Sc-EGFR-1a and Sc-EGFR-1b exhibited different proliferation patterns. Sc-EGFR-1a caused more rapid proliferation than Sc-EGFR-1b and the EGFP-N1 control. In vivo, Sc-EGFRs were successfully knocked-down for at least 15 days by injecting the clams with the dsRNA and was associated with a significant reduction in shell length. Our results reveal for the first time in mollusks the existence of alternative splicing of EGFR and provide the basis for further studies to establish the role of EGFR in growth and development of S. constricta.

View all citing articles on Scopus

View full text

Cell

ArticleFunctional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation

Abstract

J. Biol. Chem.

Cell

Biochem. Biophys. Res. Commun.

Cell

J. Mol. Biol.

Cell

Cell

J. Biol. Chem.

J. Biol. Chem.

Cell

Cell

Cell

J. Biol. Chem.

Meth. Enzymol.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

J. Biol. Chem.

Cell

Epidermal growth factor

Annu. Rev. Biochem.

Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor

Nature

Prediction of protein conformation

Biochemistry

Article
Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation